To validate the role of DSCR9 in pancreatic carcinoma cell resistance to gemcitabine, we treated noninfected, lv-NC-infected, or lv-DSCR9-infected PANC-1 and MIAPaCa-2 cell lines with gemcitabine (10 μM) for 48 h and examined cell apoptosis. The gene discussed is DSCR9; the disease is exocrine pancreatic carcinoma.